Phibro Animal Health Corp

PAHC is in an early Stage 1 consolidation with repaired short-term EMAs and a mid-July Momentum Breakout, signaling new demand. Medium-term bias is bullish as momentum overwhelms prior resistance, and short-term EMAs are rising with price tightly tracking above, justifying immediate buy participation on pullbacks into the EMA zone.

• ↑Q3 revenue $291.2M (+13% YoY) with animal health sales up 26%.
• ↑Adjusted EBITDA grew 41% YoY to $67.7M; adjusted EPS +19%.
• ↓Insiders net sold 39.7K shares; 13F institutional ownership score remains negative.